Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients / Ampliación del estudio RENACER: eficacia, seguridad y supervivencia a 12 meses de 501 pacientes de artritis reumatoide tratados con Certolizumab PEGol
Reumatol. clín. (Barc.)
; 17(1): 57-58, Ene 2021. graf, tab
Article
in English
| IBECS
| ID: ibc-211801
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Arthritis, Rheumatoid
/
Referral and Consultation
/
Tobacco Use Disorder
/
29161
/
Treatment Outcome
/
Certolizumab Pegol
Limits:
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Reumatol. clín. (Barc.)
Year:
2021
Document type:
Article
Institution/Affiliation country:
Complejo Hospital Universitario Lucus Augusti/Spain
/
Hospital Comarcal Alt Penedès/Spain
/
Hospital Comarcal de Laredo/Spain
/
Hospital General Universitario de Elche/Spain
/
Hospital Germans Tries i Pujol/Spain
/
Hospital Universitario Virgen del Rocío/Spain
/
Hospital Universitario de Guadalajara/Spain
/
Hospital Universitario del Henares/Spain